UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Unicycive announced on June 30, 2025, that the FDA 'has issued a CRL [Complete Response Letter] for its New Drug Application (NDA) for OLC to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis." The Company added that "After submitting the NDA, and as a part of the application review and routine information requests, the FDA notified Unicycive that a third-party manufacturing vendor of its main contract development and manufacturing organization (CDMO) was cited for deficiencies following a cGMP inspection." Based on this news, shares of Unicycive fell by 29.85% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Microvast Holdings (MVST) Announces Strategic Partnership with Evoy
Microvast Holdings, Inc. (NASDAQ:MVST) is one of the Best Performing EV Stocks So Far in 2025. The company has announced a strategic partnership with Evoy, which is a Norwegian company that specializes in high-output electric motor systems for boats. Notably, this collaboration is Microvast Holdings, Inc. (NASDAQ:MVST)'s debut in the electric boat segment and reflects an expansion of Evoy's battery options for diverse market applications. Notably, Evoy plans to integrate Microvast MV-I high-power battery packs into the leisure boat product line. A row of electric vehicles all powered by the company's advanced battery systems. For Q1 2025, Microvast Holdings, Inc. (NASDAQ:MVST) booked a net profit of $61.8 million and a positive adjusted EBITDA of $28.5 million, reflecting an increased demand for its advanced battery solutions as well as the effectiveness of its emphasis on profitability and operational efficiency. The company achieved record Q1 2025 revenue of $116.5 million, a strong 43.2% YoY growth. Furthermore, Microvast Holdings, Inc. (NASDAQ:MVST) continues to achieve significant traction in the commercial vehicle sector, mainly within EMEA, where it saw more than 100% growth YoY. Microvast Holdings, Inc. (NASDAQ:MVST) expects that its high-growth EMEA business will maintain strong momentum and will continue to fuel YoY revenue increases. The company has been actively pursuing new strategic partnerships in the region in order to help its current and upcoming product lines. Microvast Holdings, Inc. (NASDAQ:MVST) offers battery technologies for EVs and energy storage solutions. While we acknowledge the potential of MVST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Niu Technologies (NIU) Releases Q2 2025 Sales Volume Update
Niu Technologies (NASDAQ:NIU) is one of the Best Performing EV Stocks So Far in 2025. In Q2 2025, the company sold 350,090 units, which consisted of e-motorcycles, e-mopeds, e-bicycles, kick-scooters, and e-bikes. Furthermore, the sales in China and international markets came in at 318,719 and 31,371 units, respectively. An avid cyclist riding a sleek electric motorcycle on a rugged city street. Niu Technologies (NASDAQ:NIU) highlighted that, in China, it focused on its key product line development strategy, improving the existing models via continuous upgrades and refining the product portfolio. Notably, such efforts led to an optimized product mix, making it appealing to a range of consumers. In the international markets, Niu Technologies (NASDAQ:NIU) rolled out a comprehensive portfolio of electric motorcycles, which includes off-road models. Because of an expanded distribution network, the lineup strengthened its global market position. In China, Niu Technologies (NASDAQ:NIU) continues to advance its intelligent product development strategy through the integration of automotive-grade technologies, including millimeter-wave radar, dual-channel ABS, and an AI Smart Ecosystem. The synergistic combination of product innovation and omnichannel growth continues to fuel measurable increases across domestic sales and market penetration. The company is leveraging innovation and agile infrastructure, which can help mitigate geopolitical challenges. Niu Technologies (NASDAQ:NIU) is engaged in designing, manufacturing, and selling electric scooters. While we acknowledge the potential of NIU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Soleno Therapeutics' Vykat XR Exceeds Sales Expectations
Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the best performing mid cap stocks so far in 2025. On July 10, Soleno Therapeutics announced that the sales of its new Prader-Willi disease drug, called Vykat XR, are exceeding Wall Street expectations. Vykat XR is the first approved treatment for the insatiable hunger associated with Prader-Willi syndrome and was approved in the US on March 26 earlier this year. For the three months ending June 30, Soleno anticipates net revenue from Vykat XR sales to be between $31 and $33 million. Since its approval, the company has received ~646 'start forms' from 295 physicians, which shows strong initial demand. While the quarterly performance review is ongoing and estimates could change, Stifel analyst James Condulis noted that these preliminary numbers are well-above investor expectations. A line of biopharmaceutical products on a laboratory shelf waiting to be tested. Prader-Willi syndrome is a rare genetic condition that affects an estimated 10,000 to 20,000 people in the US, characterized by behavioral and cognitive symptoms, most notably an all-consuming hunger (hyperphagia). Before Vykat XR, the management of the disease typically involved supportive care and human growth hormone. Soleno Therapeutics Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of rare diseases. While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
